{"filings":[{"id":2420237,"accession_number":"0001193125-26-361705","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2026-08-24T10:01:23+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cytek jury verdict: noninfringement on 3 of 4 patent claims, $56.11M damages on 1 claim; appeal planned","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury found for Cytek on 3 of 4 asserted claims (noninfringement and invalidity).","One claim infringed under doctrine of equivalents; damages: $20M lost profits + $36.11M royalties.","Cytek will pursue post-verdict motions and potential appeal to Federal Circuit.","Verdict requires no changes to current products; spectral flow cytometry remains available globally.","CEO Wenbin Jiang says Cytek developed fundamentally different Full Spectrum Profiling technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-08-24","daily_digest_url":"/daily/2026-08-24","daily_digest_rank":10},{"id":2079437,"accession_number":"0001193125-26-335212","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2026-08-05T20:22:06+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Biosciences Q2 2026 revenue $48.1M (+6% YoY); net loss widens to $12.2M from $5.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $48.1M, up 6% YoY; GAAP gross margin improved to 59% from 52%.","Net loss $12.2M vs $5.6M loss YoY; adjusted EBITDA loss $1.5M vs positive $1.3M.","Operating expenses rose 15% to $39.7M, driven by litigation, severance, and personnel costs.","Full-year 2026 revenue guidance raised to $207M-$212M, midpoint up $1M.","Launched Cytek Borealis 7-laser, 60-color cytometer; installed base reached 3,933 units."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1664679,"accession_number":"0001193125-26-304789","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2026-07-15T20:15:11+00:00","items":["5.02"],"status":"ready","headline":"Cytek Biosciences enters severance and consulting agreements with former CLO Valerie Barnett","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Valerie Barnett's CLO role terminated June 29, 2026; severance lump sum of $365,775.12 plus COBRA through April 30, 2027.","If change in control occurs within 3 months, enhanced severance: 18 months base salary plus 2026 bonus target, COBRA through Jan 31, 2028, and equity acceleration.","Consulting agreement from July 10 to Aug 31, 2026 at $1,000/hour, max 10 hours/week, with continued equity vesting during term.","Previously granted equity awards under 2021 Equity Incentive Plan continue to vest subject to Continuous Service during consulting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1277677,"accession_number":"0001193125-26-282871","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2026-06-25T20:32:03+00:00","items":["5.02"],"status":"ready","headline":"Cytek Biosciences CLO Valerie Barnett to depart on June 29, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CLO and Corporate Secretary Valerie Barnett to leave Cytek effective June 29, 2026.","Departure is not due to any disagreement with company operations, policies, or practices.","Effective date of termination is June 29, 2026; no successor announced.","Filing states separation is amicable; no further details disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1083796,"accession_number":"0001193125-26-272582","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2026-06-16T20:06:14+00:00","items":["5.07"],"status":"ready","headline":"Cytek stockholders elect three Class II directors, approve advisory pay and auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three Class II directors elected: Vera Imper (64.8M for, 20.7M withheld), Glenn P. Muir (79.6M for), Ming Yan (76.7M for).","Non-binding advisory vote on 2025 executive compensation approved: 84.8M for, 0.68M against, 21K abstentions.","Ratification of Deloitte & Touche as auditor for FY2026 passed: 110.5M for, 0.48M against, 0.15M abstentions.","Broker non-votes were 25.7M shares on director elections and compensation; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":806240,"accession_number":"0001193125-26-253538","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2026-06-02T20:15:52+00:00","items":["5.02"],"status":"ready","headline":"Cytek Biosciences SVP Global Sales Philippe Busque resigns effective June 5","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Philippe Busque, Ph.D., SVP Global Sales and Services, resigned effective June 5, 2026.","Resignation is to pursue another career opportunity; not due to disagreement with company operations.","No successor or interim appointment announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95983,"accession_number":"0001193125-26-211948","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q1 revenue $44.1M (+6% YoY); net loss widens to $18.9M; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $44.1M (+6% YoY); service revenue $15.4M (+15%).","Installed base 3,789 instruments (+125 units); TTM recurring revenue 35% of total (up from 31%).","GAAP net loss $18.9M vs $11.4M; adjusted EBITDA loss $9.1M vs $3.3M loss.","G&A expenses up 43% YoY driven by litigation, consulting, and bad debt reserves.","Reaffirms FY2026 revenue guidance $205M-$212M (2-5% growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":44135000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109461,"accession_number":"0001193125-26-076768","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q4 revenue $62.1M (+8% YoY); net loss $44.1M on $38.1M deferred tax valuation allowance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 revenue $201.5M (+1% YoY); Q4 set record quarterly revenue.","GAAP gross margin 53% in Q4 vs 59% a year ago; adjusted gross margin 55% vs 61%.","Full-year net loss $66.5M vs $6.0M in 2024, driven by $33.1M non-cash deferred tax valuation allowance and higher expenses.","Adjusted EBITDA for 2025 was $5.0M, down from $22.4M; excluding investment income, was $(3.1)M.","Guides FY2026 revenue of $205-212M, representing 2-5% growth over 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":201493000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109460,"accession_number":"0001193125-26-011748","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek sees Q4 rev $62M (+8% YoY); FY2025 rev ~$201M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 revenue of ~$62M, up 8% YoY and 19% QoQ.","Full-year 2025 revenue estimated at ~$201M.","CEO cites strong Services, Reagents and APAC instrument growth; EMEA returns to positive instrument sales.","Company to present at JP Morgan Healthcare Conference on Jan 14, 2026.","Full Q4 and FY results with 2026 guidance expected late February 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":201493000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125965,"accession_number":"0001193125-25-266973","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q3 2025 net loss $5.5M; adjusted EBITDA $2.5M; revenue +2% to $52.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $52.3M, +2% YoY; installed base 3,456 instruments (+161 units in Q3).","GAAP net loss $5.5M vs net income $0.9M in Q3 2024; GAAP gross margin 53% vs 56%.","Adjusted EBITDA $2.5M vs $7.6M in prior year; ex-investment income $0.5M vs $5.7M.","Recurring revenue up 19% YoY; biopharma/CRO revenue up 14% YoY.","FY2025 revenue guidance reaffirmed $196M-$205M (-2% to +2% growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":139352000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142707,"accession_number":"0001193125-25-174459","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q2 2025 revenue $45.6M (-2% YoY); narrows 2025 guidance to $196-205M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $45.6M, down 2% YoY; net loss $5.6M vs $10.4M loss in Q2 2024.","Adjusted EBITDA $1.3M (down from $2.9M); operating loss $10.6M vs $8.5M.","Installed base grew to 3,295 instruments (146 new units); launched Aurora Evo system.","Recurring revenue up 16% YoY; repurchased $4.5M in stock during Q2.","2025 revenue guidance narrowed to $196-205M (flat to -2% growth over 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":87059000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160772,"accession_number":"0001193125-25-145725","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cytek director nominee Deborah Neff fails election; other proposals pass","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deborah Neff received 33.8M votes for vs. 48.2M withheld, failing to be elected as Class I director.","Richard Chin was re-elected with 81.8M votes for and 0.2M withheld.","Advisory say-on-pay proposal passed with 76.4M votes for (93.1% of votes cast excluding broker non-votes).","Ratification of Deloitte & Touche as auditor passed with 95.9M for (92.3% of votes cast).","Quorum of 81.4% of outstanding shares represented at the June 18, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160771,"accession_number":"0001193125-25-115965","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q1 revenue down 7.6% to $41.5M; net loss widens; FY2025 guidance reduced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $41.5M (-7.6% YoY); gross margin 49% vs 51%; net loss $11.4M vs $6.2M loss prior year.","Adjusted EBITDA loss $3.3M vs $0.7M loss; cash & securities $265.6M, down $12.3M from Dec 2024.","FY2025 revenue guidance revised to $196-210M (-2% to +5% YoY); prior guidance withdrawn.","Repurchased $10.6M of common stock in Q1; launched Cytek Muse Micro instrument.","Strength in APAC and cell sorters/service business offset by US/EMEA product sales slowdown."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":41457000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178972,"accession_number":"0001193125-25-039225","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Biosciences Q4 rev $57.5M (-1.3%); FY24 net loss $6.0M; guides FY25 rev $204-212M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 revenue $200.5M (+3.9% YoY); Q4 revenue $57.5M (-1.3% YoY, +1.4% constant currency).","Net loss improved to $6.0M from $12.1M in 2023; adjusted EBITDA $22.4M (+77% YoY).","Installed base reached 3,034 instruments; 667 placed in 2024.","Board authorized new $50M stock repurchase program for 2025; $21.6M repurchased in 2024.","2025 revenue guidance $204-212M (2-6% growth); opened Singapore manufacturing facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":200453000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178971,"accession_number":"0001193125-25-006599","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Biosciences expects FY2024 revenue $200-201M, 4% growth; Q4 rev up 11-13% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 revenue expected $200-201M, up 4% from $193M in 2023; ~$1M negative FX impact.","Q4 2024 revenue $57-58M, 11-13% sequential growth, down 2% to flat YoY; FX reduced Q4 by ~$1.5M.","CEO cites strong APAC and Rest of World growth, offset by order delays and USD strength.","Preliminary results unaudited; full earnings and 2025 guidance expected late February 2025.","Company to present at J.P. Morgan Healthcare Conference on January 16, 2025 in San Francisco."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":200453000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195657,"accession_number":"0001193125-24-251268","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q3 revenue $51.5M (+7% YoY); net income $0.9M vs loss year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $51.5M, up 7% vs Q3 2023; year-to-date revenue $143.0M, up 6%.","GAAP net income $0.9M vs net loss of $6.5M in Q3 2023; adjusted EBITDA $7.6M vs $3.7M.","Installed base expanded to 2,821 units, adding 164 units in Q3.","Repurchased $12.1M of stock during Q3; cash and securities $277.8M.","FY2024 revenue guidance reaffirmed at $203-210M, expecting positive operating cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":142977000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211920,"accession_number":"0001193125-24-217558","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cytek Biosciences COO Paul Christopher Williams resigns effective Sept 27, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Paul Christopher Williams resigned on Sept 9, 2024, effective Sept 27, 2024, to pursue another career opportunity.","No replacement has been named; CEO Wenbin Jiang remains in charge.","Resignation is voluntary and not due to any disagreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211919,"accession_number":"0001193125-24-194907","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q2 revenue $46.6M, -6% YoY; net loss widens to $10.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $46.6M (-6% YoY, +4% QoQ); GAAP gross margin 55% (adjusted 58%).","Net loss $10.4M vs $4.4M in Q2 2023; operating loss $8.5M vs $9.1M.","Adjusted EBITDA $2.9M vs $1.5M; cash and securities $277.2M.","FY2024 revenue guidance narrowed to $203-210M (5-9% growth); expects positive cash flow from ops.","Repurchased $2.7M of stock; total installed base 2,656 instruments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":91477000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230711,"accession_number":"0001193125-24-159094","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cytek Biosciences 2024 annual meeting results: all proposals approved by shareholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Wenbin Jiang and Michael Holder as Class III directors with 64.2M and 70.3M votes for, respectively.","Advisory vote on executive compensation approved: 63.5M for, 10.5M against, 78.9K abstentions.","Ratified Deloitte & Touche LLP as independent auditor for FY2024: 94.1M for, 2.3M against, 656.7K abstentions.","Approximately 74% of outstanding shares (97.1M of 131.3M) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230710,"accession_number":"0001193125-24-134238","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q1 revenue $44.9M (+21% YoY); organic revenue up 11%; reaffirms 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $44.9M, +21% YoY; organic revenue (ex-Luminex) $37.3M, +11%.","Gross profit margin 51% (down from 57%); adjusted gross margin 55% (down from 59%).","Net loss $6.2M vs $6.8M loss; Adjusted EBITDA loss $0.7M vs $2.5M loss.","Reaffirms 2024 revenue guidance $203M-$213M (5-10% growth); expects positive net income for FY2024.","Appointed William McCombe as CFO; opened new facility in Wuxi, China; received NMPA approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":44860000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249099,"accession_number":"0001193125-24-071467","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cytek Biosciences appoints William McCombe as CFO, reaffirms 2024 revenue guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrik Jeanmonod steps down as CFO to become Head of Corporate Development Analytics, effective March 17, 2024.","William McCombe appointed CFO effective March 18, 2024; base salary $420,000, target bonus 50%, equity grant $1.25M.","McCombe previously CFO at Velo3D, HZO, and Maxar Technologies; over 20 years investment banking experience.","Cytek reaffirms 2024 revenue guidance of $203M-$213M (5-10% growth) and expectation of positive net income.","No disagreement cited for Jeanmonod's transition; company reiterates 2024 outlook unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249098,"accession_number":"0001193125-24-054312","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Biosciences Q4 revenue up 21% to $58.6M; full year net loss $11.3M; guides 5-10% growth for 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue Q4 $58.6M (+21% YoY); organic $48.8M (+1%); full year $193.4M (+18%).","Q4 net income $6.3M vs $3.7M; full year net loss $11.3M vs income $2.5M.","2024 revenue guidance $203M-$213M (5-10% growth); expects positive net income.","Repurchased 5.3M shares for $34.7M in Q4; 6.6M total since May 2023.","Introduced Cytek Orion automated antibody cocktail prep system."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249097,"accession_number":"0001193125-24-046891","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cytek Biosciences amends severance plan; CEO gets 12-month base, 24-month on change of control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved Second Amended and Restated Severance Benefit Plan effective Feb 20, 2024.","Non-CIC termination: CEO receives 12 months base salary + COBRA; other NEOs get 9 months base + COBRA.","CIC termination: CEO receives 24 months base salary + 100% target bonus + 24 months COBRA + full equity vesting.","Other NEOs get 18 months base salary + 100% target bonus + 18 months COBRA + full equity vesting.","Benefits require signed release and compliance with restrictive covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249096,"accession_number":"0001193125-24-004805","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Biosciences prelim FY2023 revenue near high end of $188M-$192M guidance","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary full-year 2023 revenue expected near high end of prior guidance range of $188M-$192M.","Final Q4 and FY2023 results and 2024 guidance to be reported on expected earnings call in late February 2024.","CEO Wenbin Jiang to present at 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":193015000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266619,"accession_number":"0001193125-23-283662","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cytek Biosciences posts updated corporate presentation, no material new info disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing references updated corporate presentation made available on company website.","Presentation slide lists CEO Dr. Wenbin Jiang, CFO Patrik Jeanmonod, and IR Paul Goodson.","No specific financial figures, guidance changes, or operational updates are provided in the filing or exhibit.","The 8-K furnishes the presentation under Regulation FD; content not incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266618,"accession_number":"0001193125-23-274005","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Biosciences reports Q3 2023 earnings; no financial details in furnished transcript","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company announced preliminary financial results for quarter ended September 30, 2023.","Conference call held on November 7, 2023; transcript furnished as Exhibit 99.1.","Transcript excerpt provided does not include specific revenue, EPS, or guidance figures.","CEO Wenbin Jiang and CFO Patrik Jeanmonod participated in the call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":134782000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266617,"accession_number":"0001193125-23-272504","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q3 revenue $48M (+19%), organic growth 2%; net loss $6.5M; FY guidance $188-192M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $48.0M (+19% YoY); organic revenue $41.2M (+2%); acquired Luminex contributed $6.8M.","Gross profit margin 57% vs 66% prior year; adjusted gross margin 59% vs 68%.","Operating loss $6.4M vs income $1.4M; net loss $6.5M vs net income $1.6M; adjusted EBITDA $3.7M vs $7.3M.","FY 2023 revenue guidance $188-192M (15-17% growth); organic expected flat vs 2022.","Repurchased 1,155,229 shares at $8.4M; cash $288M, down from $344M at Dec 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":134782000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283855,"accession_number":"0001193125-23-206235","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q2 revenue up 24% to $49.7M; net loss widens to $4.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $49.7M (+24% YoY); organic revenue $41.5M (+3%) excl. $8.2M from Luminex acquisition.","Gross margin 57% vs 61% YoY; adjusted gross margin 60% vs 64%.","Operating loss $9.1M (vs $0.9M loss Q2 2022); net loss $4.4M (vs $0.7M).","Adjusted EBITDA $1.5M vs $4.8M prior year; cash $298.8M.","Shipped 100th Cytek Aurora Cell Sorter; FY2023 revenue guidance reaffirmed at $205M-$220M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":86781000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303438,"accession_number":"0001193125-23-169513","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cytek Biosciences shareholders elect three Class II directors and approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three director nominees (Jack Ball, Vera Imper, Ming Yan) elected with 55.9M–56.9M votes for; broker non-votes 25.6M.","Advisory vote on 2022 executive compensation passed with 57.4M for, 1.4M against, 0.8M abstentions.","Advisory vote on frequency of say-on-pay: one-year option received 58.6M votes; two- and three-year options negligible.","Ratification of Deloitte & Touche as auditor for FY2023 approved with 84.9M for, 11k against.","Approximately 63% of outstanding shares (85.2M of 135.7M) represented at the 2023 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303436,"accession_number":"0001193125-23-144952","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K/A","filed_at":"2023-05-15T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Cytek acquired flow cytometry business with $43.1M revenue, $4.4M loss in 2022","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price was $46.5M less $1.6M working capital adjustments and transaction fees.","Net assets acquired: $44.1M assets, $5.7M liabilities, net $38.4M as of Dec 31, 2022.","FY2022 revenue: $43.1M (product $32.3M, service $10.8M); direct expenses $47.5M.","Abbreviated financials exclude corporate overhead, taxes, interest; not a standalone entity.","Acquired brands include Amnis, CellStream, Guava, Muse; closing occurred Feb 28, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303437,"accession_number":"0001193125-23-139445","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q1 revenue $37.1M (+6% YoY); net loss widens to $6.8M; organic revenue -4%; revises FY23 outlook to $205-220M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $37.1M, up 6% YoY; constant-currency revenue $38.1M (+9%).","Organic revenue (ex-Luminex) $33.7M, down 4% YoY; U.S. pharma/biotech weakness cited.","Net loss $6.8M vs $2.2M loss in Q1 2022; adjusted EBITDA -$2.5M vs +$1.9M.","Completed Luminex flow cytometry asset acquisition for $44.9M on Feb 28, 2023; contributed $3.4M revenue.","Revised FY2023 revenue guidance to $205-220M (25-34% growth), citing macro uncertainties and longer sales cycles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":37088000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323071,"accession_number":"0001193125-23-053897","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q4 revenue $48.3M (+24% YoY); guides FY2023 $225-235M (+37-43%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2022 revenue $164.0M, up 28% YoY (34% constant currency); net income $2.5M.","Q4 net income $3.7M vs loss $1.2M in Q4 2021; adjusted EBITDA $6.6M.","2023 revenue guidance $225-235M, including ~$20M from Luminex acquisition closed Feb 28.","Acquired Luminex's Flow Cytometry and Imaging business; partnership with Bio-Rad.","Cash and short-term investments $341.1M; 560 instrument placements in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":164036000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323070,"accession_number":"0001193125-23-052702","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Cytek Biosciences completes $46.5M acquisition of Luminex flow cytometry assets","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed acquisition of Luminex's flow cytometry and imaging business (Amnis, CellStream, Guava, Muse brands) on Feb 28, 2023.","Purchase price approximately $46.5 million in cash, subject to customary adjustments at closing.","Company assumed certain liabilities of the acquired business.","Financial statements and pro forma information to be filed within 71 days after this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323069,"accession_number":"0001193125-23-035865","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2023-02-13T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cytek Biosciences to acquire flow cytometry & imaging assets from Luminex for $46.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price ~$46.5M cash; deal expected to close within 30 days; includes >7,000 installed instruments.","Acquires Amnis imaging and Guava flow cytometers; >60% of FCI employees are commercial, boosting Cytek's sales and service.","Acquisition aligns with DiaSorin's strategic priorities; Cytek expands global footprint and adds entry-level instrument options.","Cytek to host investor conference call Feb 13 at 4:30 PM ET; details at investors.cytekbio.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341143,"accession_number":"0001193125-22-281247","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q3 revenue $40.5M (+18% YoY); net income $1.6M; guides FY near high end of $160-168M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $40.5M (+18% YoY); gross margin improved to 66.4% from 61.9%.","Net income $1.6M (vs $1.4M); adjusted EBITDA $7.3M (vs $5.5M).","FY2022 revenue guidance reaffirmed closer to high end of $160M-$168M range.","Appointed Chris Williams as Chief Operating Officer during the quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":115700000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341142,"accession_number":"0001193125-22-275058","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cytek Biosciences appoints Chris Williams as COO, effective Oct. 31, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Williams appointed COO, reporting to CEO Wenbin Jiang; focused on scaling global operations.","Annual base salary of $395,000; target bonus 50% of base; $100,000 sign-on cash bonus (clawback within 12 months).","Equity grants of $500,000, split 50% stock options and 50% RSUs, vesting over four years.","Williams previously VP at Thermo Fisher Scientific and Bayer Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358241,"accession_number":"0001193125-22-217376","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q2 revenue $40.2M (+32% YoY); net loss of $0.7M vs prior-year net income $2.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $40.2M, up 32% YoY; gross profit $24.6M (61% margin) vs $19.7M (65% margin) prior year.","Operating loss $0.9M vs operating income $3.8M in Q2 2021; net loss $0.7M vs prior net income $2.7M.","Adjusted EBITDA $4.8M flat YoY; installed base 1,356 instruments (130 placed in quarter).","Full-year 2022 revenue guidance reaffirmed: closer to high end of $160M-$168M range.","Received CE mark for cFluor reagents and TBNK kit for European clinical market."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":75223000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376977,"accession_number":"0001193125-22-168332","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2022-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cytek Biosciences reports 2022 annual meeting voting results; Class I directors elected and auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Deborah Neff and Don Hardison elected as Class I directors with ~88.7M and ~88.7M votes for, respectively.","Ratification of Deloitte & Touche as auditor for FY2022 approved with 115.4M votes for, 5,450 against.","Approximately 86% of outstanding shares (116M out of 134.2M) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376976,"accession_number":"0001193125-22-147538","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q1 revenue up 44% to $35.1M; raises FY2022 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $35.1M, +44% YoY; installed base grew to 1,226 instruments with 116 new placements.","GAAP net loss of $2.2M vs net income of $0.1M last year; operating loss $2.4M vs income $1.1M.","Adjusted EBITDA $1.9M, up from $1.1M; adjusted gross margin 61% vs 60%.","FY2022 revenue guidance raised to high end of $160M-$168M range.","Service revenue more than doubled from prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":35064000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395317,"accession_number":"0001193125-22-063025","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2022-03-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cytek sets 2022 executive comp: salaries, bonuses, equity grants","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Wenbin Jiang: 2022 base salary $545,000, target bonus 80% of base.","CTO Ming Yan: base $400,000, target bonus 50%; CFO Patrik Jeanmonod: base $385,000, target 50%.","Equity grants: CEO 163,158 options + 108,137 RSUs; CTO 47,841 options + 31,708 RSUs; CFO 42,310 options + 28,042 RSUs.","Options exercise price $13.64, vesting over 4 years; RSUs vest quarterly over 4 years.","2021 cash bonuses: CEO $163,687, CTO $134,451, CFO $106,492."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395316,"accession_number":"0001193125-22-050077","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2022-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q4 revenue $38.9M (+27% YoY); FY2021 revenue $128M (+38%); guides FY2022 $160-168M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $38.9M (+27% YoY); FY2021 revenue $128.0M (+38% YoY).","Q4 net income $0.3M (vs $5.6M in Q4 2020); FY net income $4.4M (vs $19.4M in 2020).","Adjusted EBITDA Q4 $5.5M; FY $17.5M, up from $15.4M in 2020.","Installed base 1,110 instruments; 453 instrument placements in FY2021.","FY2022 revenue guidance $160-168M, representing 25-31% growth over FY2021."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":127950000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395315,"accession_number":"0001193125-22-003544","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2022-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cytek Biosciences appoints Dr. Vera Imper to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from six to seven members; Dr. Imper appointed as Class II director effective Dec 31, 2021.","Dr. Imper receives $40,000 annual retainer and initial equity award of $300,000 (28,598 option shares at $16.32).","Initial options vest monthly over three years; annual equity grant of $160,000 at 2022 annual meeting.","Dr. Imper determined independent under Nasdaq rules; standard indemnification agreement in place."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414035,"accession_number":"0001193125-21-323057","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q3 revenue $34.4M (+37% YoY); net income $1.6M down from $6.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $34.4M, up 37% YoY; gross margin 62% (non-GAAP 64%).","Net income $1.6M, down from $6.5M YoY; non-GAAP net income $4.1M vs $6.7M.","Operating expenses $18.3M, up 106% YoY due to public company costs and R&D investment.","Cash $377M; installed base expanded to 970 instruments with 115 placements in Q3.","Announced acquisition of Tonbo Biosciences' cell analysis business to enhance reagent portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":89056000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432395,"accession_number":"0001193125-21-265510","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2021-09-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Biosciences Q2 revenue $30.4M (+59% YoY); operating income turns positive at $3.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $30.4M, +59% YoY; gross margin improved to 65% from 43%.","Operating income $3.8M vs. ($0.2M) a year ago; net income $2.7M down from $8.1M.","Installed base reached 855 instruments, with 104 placements in Q2.","Launched Aurora Cell Sorter and Automated Sample Loader during the quarter.","Completed IPO in July 2021, raising $215M in net proceeds to strengthen balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432394,"accession_number":"0001193125-21-260590","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2021-08-30T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Cytek enters non-exclusive laser supply agreement with Coherent NA","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Supply Agreement with Coherent NA for laser products; no minimum purchase obligation.","Cytek submits non-binding rolling forecasts; orders accepted only upon Coherent written acknowledgement.","Initial term of 3 years with automatic 1-year renewal unless 4-month non-renewal notice given.","No financial terms or volume commitments disclosed; agreement deemed routine supplier arrangement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432393,"accession_number":"0001193125-21-225716","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2021-07-27T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Cytek Biosciences closes IPO of 14.56M shares at $17.00 per share, raising $200M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed IPO on July 27, 2021; issued 14,564,635 shares at $17.00 per share.","Gross proceeds to company were $200 million before underwriting discounts and expenses.","Offering included 11,764,706 shares by company and 2,799,929 shares by selling stockholders.","Filed amended and restated certificate of incorporation and bylaws effective upon closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}